The island supported biopharmaceutical consort PharmaEssentia Corp. is investigating P1101, its third-generation PEG-interferon-alpha take candidate. Because it is a longer-lasting, purer interferon that is inferior expensive to produce, P1101 could compound the communication options for Hepatitis B and C….

Tags: ATM, Treatment Option